75308-46-2

Basic information

• Product Name: tert-Butyl 2,6-dichloroisonicotinate
• Synonyms: tert-Butyl 2,6-dichloro-4-pyridinecarboxylate;TERT-BUTYL 2,6-DICHLOROISONICOTINATE;2,6-dichloro-4-pyridinecarboxylic acid 1,1-dimethylethyl ester;2,6-Dichloroisonicotinic acid tert-butyl ester;2,6-Dichloroisonicotinic Acid t-butyl ester;tert-Butyl 2,6-Dichloropyridine-4-carboxylate;2,6-Dichloroisonicotinic Acid tert-Butyl Ester tert-Butyl 2,6-Dichloro-4-pyridinecarboxylate 2,6-Dichloro-4-pyridinecarboxylic Acid tert-Butyl Ester;tert-Butyl 2,6-Dichloroisonicotinate
• CAS NO: 75308-46-2
• Molecular Formula: C₁₀H₁₁Cl₂NO₂
• Molecular Weight: 248.11
• Mol File: 75308-46-2.mol
• Article Data: 17

Chemical Properties

• Melting Point: 80.0 to 84.0 °C
• Boiling Point: 326°C
• Flash Point: 151°C
• Appearance: /
• Density: 1.278
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.528
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.43±0.10(Predicted)
• CAS DataBase Reference: tert-Butyl 2,6-dichloroisonicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 2,6-dichloroisonicotinate(75308-46-2)
• EPA Substance Registry System: tert-Butyl 2,6-dichloroisonicotinate(75308-46-2)

Safety Data

• Hazardous Substances Data: 75308-46-2(Hazardous Substances Data)

Usage

General Description

Tert-Butyl 2,6-dichloroisonicotinate is a chemical compound that belongs to the class of isonicotinic acid derivatives. It is a white solid substance that is commonly used in the pharmaceutical industry for the synthesis of various drugs and pharmaceutical compounds. This chemical is known for its diverse pharmacological activities, including anti-inflammatory, antiviral, and antibacterial properties. It is also used as an intermediate in the production of agrochemicals, dyes, and pigments. Tert-Butyl 2,6-dichloroisonicotinate has attracted attention for its potential therapeutic applications in the treatment of various diseases, making it a valuable compound in the field of medicinal chemistry.

InChI:InChI=1/C10H11Cl2NO2/c1-10(2,3)15-9(14)6-4-7(11)13-8(12)5-6/h4-5H,1-3H3

Upstream product

• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 
• 71432-55-8 2-tert-butyl-1,3-diisopropylisourea 
• 115-11-7 isobutene 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1604-14-4 2,6-dichloroisonicotinic acid ethyl ester 
• 1062669-89-9 4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenol 
• 1062670-10-3 (S)-N,N-diethyl-4-(3-(3-ethyl-5-methyl-4-(oxiran-2-ylmethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-6-methylpyridin-2-amine 
• 1062670-07-8 (S)-1-amino-3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)propan-2-ol 
• 1062671-08-2 4-[3-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-2-ethyl-6-methyl-phenol 
• 1062671-14-0 C₂₄H₃₃N₅O₃ 
• 1062671-23-1 {4-[5-(4-benzyloxy-3-ethyl-5-methylphenyl)-[1,3,4]oxadiazol-2-yl]-6-methylpyridin-2-yl}diethylamine 
• 1062671-19-5 4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenol 
• 1062671-30-0 C₂₄H₃₃N₅O₃ 
• 1062670-13-6 (S)-N-(3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1062671-18-4 (S)-N-(3-(4-(3-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,2,4]oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1062671-33-3 (S)-N-(3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,3,4]oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1062669-94-6 (S)-3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)propane-1,2-diol 
• 1062671-27-5 (S)-3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,3,4]oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)propane-1,2-diol 

Relevant articles and documents

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Practical and scalable synthesis of S1P1 receptor agonist ACT-209905

A practical and scalable route for the fast delivery of 12 kg of S1P 1 agonist (ACT-209905) has been developed. ACT-209905 is composed of an amino pyridine group, an oxadiazole spacer, a 2-ethyl-5-methylphenol moiety and a chiral 1-amino-2-propanol side chain. The convergent synthesis consists of 16 steps with 9 isolated intermediates and is chromatography-free. Key building blocks are accessed from low-cost starting materials, such as acetone, diethyl oxalate, cyanoacetamide, and 2-ethyl-5-methyl aniline. A Negishi coupling that was troubled by the use of metal reagents and concomitant metal waste streams has been replaced by a less expensive Guareschi-Thorpe reaction to build up an amino isonicotinic acid. The chiral 1-amino-2-propanol moiety was secured by selective ring-opening of an epoxide with lithium hexamethyldisilazide as an ammonia surrogate, thus omitting the notorious double alkylated byproduct.

Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.